FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328104940> ?p ?o ?g. }

• W4328104940 endingPage "951" @default.
• W4328104940 startingPage "940" @default.
• W4328104940 abstract "Introduction D-1553 (garsorasib) is a potent and selective oral KRASG12C inhibitor. We report results from a phase I dose-escalation and dose-expansion study of D-1553 in patients with KRAS G12C–mutated NSCLC in multiple sites in the People’s Republic of China. Methods Patients with KRAS G12C–mutated NSCLC have administrated D-1553 600 mg orally once daily, 800 mg once daily, 1200 mg once daily, 400 mg twice a day, or 600 mg twice a day in dose escalation. In dose-expansion, all patients received 600 mg twice a day. The safety, pharmacokinetics, and efficacy of D-1553 were evaluated. Results Among a total of 79 treated patients, 75 patients (94.9%) reported treatment-related adverse events with 30 patients experiencing grade 3 or 4 events (38.0%). Most of the adverse events were manageable and the patients tolerated the study treatment well. Among 74 patients assessable for efficacy analysis, 30 patients had a partial response and 38 had stable disease with a confirmed objective response rate (ORR) and disease control rate (DCR) of 40.5% and 91.9%, respectively. The median progression-free survival was 8.2 months, and the median duration of response was 7.1 months. Among 62 patients assessable for response at the recommended phase 2 dose, partial response occurred in 24 patients (ORR, 38.7%) and stable disease in 32 patients (DCR, 90.3%). The median progression-free survival and duration of response were 7.6 months and 6.9 months, respectively. In patients with brain metastasis, ORR and DCR were 17% and 100%, respectively. Conclusions D-1553 represents a promising therapeutic option for patients with KRAS G12C–mutated NSCLC with a well-tolerated safety profile and encouraging antitumor activity." @default.
• W4328104940 created "2023-03-22" @default.
• W4328104940 creator A5002237217 @default.
• W4328104940 creator A5004928583 @default.
• W4328104940 creator A5007452056 @default.
• W4328104940 creator A5011766161 @default.
• W4328104940 creator A5015381775 @default.
• W4328104940 creator A5030035495 @default.
• W4328104940 creator A5037204705 @default.
• W4328104940 creator A5039405375 @default.
• W4328104940 creator A5041450037 @default.
• W4328104940 creator A5048154323 @default.
• W4328104940 creator A5049277287 @default.
• W4328104940 creator A5049433169 @default.
• W4328104940 creator A5052115827 @default.
• W4328104940 creator A5055526321 @default.
• W4328104940 creator A5056492561 @default.
• W4328104940 creator A5063162812 @default.
• W4328104940 creator A5064787014 @default.
• W4328104940 creator A5066879163 @default.
• W4328104940 creator A5071321024 @default.
• W4328104940 creator A5072537482 @default.
• W4328104940 creator A5076756498 @default.
• W4328104940 creator A5077147157 @default.
• W4328104940 creator A5083228843 @default.
• W4328104940 creator A5085215477 @default.
• W4328104940 creator A5088888346 @default.
• W4328104940 creator A5089852487 @default.
• W4328104940 date "2023-07-01" @default.
• W4328104940 modified "2023-10-12" @default.
• W4328104940 title "D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results" @default.
• W4328104940 cites W1599750485 @default.
• W4328104940 cites W1991874467 @default.
• W4328104940 cites W2050126859 @default.
• W4328104940 cites W2057209504 @default.
• W4328104940 cites W2085739080 @default.
• W4328104940 cites W2109031404 @default.
• W4328104940 cites W2128339707 @default.
• W4328104940 cites W2465450966 @default.
• W4328104940 cites W2466033276 @default.
• W4328104940 cites W2560367892 @default.
• W4328104940 cites W2796153225 @default.
• W4328104940 cites W2886790097 @default.
• W4328104940 cites W2922251729 @default.
• W4328104940 cites W2976596814 @default.
• W4328104940 cites W3001136978 @default.
• W4328104940 cites W3014882016 @default.
• W4328104940 cites W3037353473 @default.
• W4328104940 cites W3087229737 @default.
• W4328104940 cites W3118321568 @default.
• W4328104940 cites W3128646645 @default.
• W4328104940 cites W3134146062 @default.
• W4328104940 cites W3172081492 @default.
• W4328104940 cites W3182774311 @default.
• W4328104940 cites W3205284338 @default.
• W4328104940 cites W3212888956 @default.
• W4328104940 cites W3213005505 @default.
• W4328104940 cites W4214569871 @default.
• W4328104940 cites W4226195336 @default.
• W4328104940 cites W4226509968 @default.
• W4328104940 cites W4231423004 @default.
• W4328104940 cites W4281650778 @default.
• W4328104940 cites W4296768674 @default.
• W4328104940 doi "https://doi.org/10.1016/j.jtho.2023.03.015" @default.
• W4328104940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36948246" @default.
• W4328104940 hasPublicationYear "2023" @default.
• W4328104940 type Work @default.
• W4328104940 citedByCount "2" @default.
• W4328104940 countsByYear W43281049402023 @default.
• W4328104940 crossrefType "journal-article" @default.
• W4328104940 hasAuthorship W4328104940A5002237217 @default.
• W4328104940 hasAuthorship W4328104940A5004928583 @default.
• W4328104940 hasAuthorship W4328104940A5007452056 @default.
• W4328104940 hasAuthorship W4328104940A5011766161 @default.
• W4328104940 hasAuthorship W4328104940A5015381775 @default.
• W4328104940 hasAuthorship W4328104940A5030035495 @default.
• W4328104940 hasAuthorship W4328104940A5037204705 @default.
• W4328104940 hasAuthorship W4328104940A5039405375 @default.
• W4328104940 hasAuthorship W4328104940A5041450037 @default.
• W4328104940 hasAuthorship W4328104940A5048154323 @default.
• W4328104940 hasAuthorship W4328104940A5049277287 @default.
• W4328104940 hasAuthorship W4328104940A5049433169 @default.
• W4328104940 hasAuthorship W4328104940A5052115827 @default.
• W4328104940 hasAuthorship W4328104940A5055526321 @default.
• W4328104940 hasAuthorship W4328104940A5056492561 @default.
• W4328104940 hasAuthorship W4328104940A5063162812 @default.
• W4328104940 hasAuthorship W4328104940A5064787014 @default.
• W4328104940 hasAuthorship W4328104940A5066879163 @default.
• W4328104940 hasAuthorship W4328104940A5071321024 @default.
• W4328104940 hasAuthorship W4328104940A5072537482 @default.
• W4328104940 hasAuthorship W4328104940A5076756498 @default.
• W4328104940 hasAuthorship W4328104940A5077147157 @default.
• W4328104940 hasAuthorship W4328104940A5083228843 @default.
• W4328104940 hasAuthorship W4328104940A5085215477 @default.
• W4328104940 hasAuthorship W4328104940A5088888346 @default.
• W4328104940 hasAuthorship W4328104940A5089852487 @default.
• W4328104940 hasConcept C112705442 @default.
• W4328104940 hasConcept C121608353 @default.

• next